Merck said the European Commission has approved the use of its Keytruda to treat adult patients with Hodgkin's lymphoma in some instances, allowing the company to market the drug throughout the European Union and in Iceland, Lichtenstein and Norway at an approved dose of 200 milligrams every three weeks with doctor supervision.

Celgene said its phase III RADIANCE trial of oral drug ozanimod decreased the calculated relapse rate in patients with relapsing multiple sclerosis (RMS).

Lupus patient advocates are planning to hold the Lupus Patient-Focused Drug Development (PFDD) Meeting, titled Lupus: Patient Voices, on Sept. 25 in the Washington, D.C., area, a release on the Lupus Foundation of America website said.

Boehringer Ingelheim said it presented the analysis of data from two Phase III INPULSIS trials at the 2017 American Thoracic Society (ATS) conference.

The American Academy of Physicians Assistants (AAPA) and CancerLinQ are teaming up to advance research in cancer care, a release on the American Society of Clinical Oncology website said.

EUSA Pharma said the European Commission approved the antibody ch14.18/CHO, dinutuximab beta, to treat children at least 1-year-old affected by neuroblastoma, a form of childhood cancer.

A study published in the American Heart Association (AHA) journal Stroke showed that women with preeclampsia run a higher risk of pregnancy-related stroke.

A Merck drug credited by strong Phase 3 clinical data for HIV-1 suppression despite its possibility of deadly skin side effects has been approved by the U.S. Food and Drug Administration for once-daily doses along with other antivirals.

Zykadia, a drug found to double the life expectancy of certain lung cancer patients, now has authorization from the Food & Drug Administration for use as an initial treatment for the disease once it has spread to the brain.

The Food and Drug Administration has authorized Keytruda, a new Merck & Co. Inc. medication, to treat cancer patients with solid tumors that have withstood three standard-of-care drugs.

The American Heart Association's CEO Nancy Brown praised the Centers for Medicare and Medicaid Services (CMS) for the final decision allowing Medicare patients to receive supervised exercise therapy (SET) for symptomatic peripheral artery disease (PAD).

The results of testing on three new medicines from AstraZeneca for bladder, ovarian and lung cancer will be announced at the June meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Merck has entered into an exclusive global license agreement with Teijin Pharma.

The National Institutes of Health (NIH) said real-time monitoring offers a promising tool for studying the progression of influenza and other diseases.

The American College of Cardiology, the American Heart Association (AHA) and the Heart Failure Society of America have released a second update to a guideline for heart failure management, AHA said in a release.

Bristol-Myers Squibb said it will collaborate with Advaxis Inc. in a study to evaluate ADXS-DUAL and Opdivo (nivolumab) in a combination therapy for cervical cancer that has resisted or recurred after chemotherapy.

Novartis said in a release that expanded use of Zykadia to include the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive has been recommended by the the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).

Novartis said it presented its latest data on oncology at the recent 53rd annual meeting of the American Society of Clinical Oncology in Chicago.

AstraZenica said it presented positive results of the Phase III OlympiAD trial of Lynparza (olaparib) on patients with HER2-negative gBRCA-mutated metastatic breast cancer at the 2017 American Society of Clinical Oncology (ASCO) meeting in Chicago, and the results were also published in the New England Journal of Medicine.

Bristol-Myers Squibb said it is partnering with Novartis to investigate using Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in combination with Mekinist (trametinib) for treating metastatic colorectal cancer.